Gemina Laboratories Ltd
Gemina Laboratories Ltd., a biotechnology company, engages in the research, development, and commercialization of in-vitro diagnostics in Canada. The company's products include LEGIO X COVID-19, a COVID-19 rapid antigen test; and LEGIO X Influenza AB, an influenza AB multiplex lateral flow test. It also develops respiratory syncytial virus and tuberculosis. Gemina Laboratories Ltd. was incorporat… Read more
Gemina Laboratories Ltd (GLABF) - Total Liabilities
Latest total liabilities as of January 2025: $5.87 Million USD
Based on the latest financial reports, Gemina Laboratories Ltd (GLABF) has total liabilities worth $5.87 Million USD as of January 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Gemina Laboratories Ltd - Total Liabilities Trend (2021–2025)
This chart illustrates how Gemina Laboratories Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Gemina Laboratories Ltd Competitors by Total Liabilities
The table below lists competitors of Gemina Laboratories Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Sernova Corp
OTCQB:SEOVF
|
USA | $25.84 Million |
|
Sotherly Hotels Inc
NASDAQ:SOHO
|
USA | $374.63 Million |
|
Silver One Resources Inc
OTCQX:SLVRF
|
USA | $980.72K |
|
Electrocore LLC
NASDAQ:ECOR
|
USA | $22.48 Million |
|
Medicalg
WAR:MDG
|
Poland | zł40.01 Million |
|
Archer Materials Limited
PINK:ARRXF
|
USA | $752.16K |
|
YAS Co., Ltd.
KQ:255440
|
Korea | ₩37.46 Billion |
|
Top High Image
TWO:3284
|
Taiwan | NT$1.60 Billion |
Liability Composition Analysis (2021–2025)
This chart breaks down Gemina Laboratories Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.02 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.32 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 4.08 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Gemina Laboratories Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Gemina Laboratories Ltd (2021–2025)
The table below shows the annual total liabilities of Gemina Laboratories Ltd from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-01-31 | $5.87 Million | +93.11% |
| 2024-01-31 | $3.04 Million | +56.23% |
| 2023-01-31 | $1.95 Million | +309.06% |
| 2022-01-31 | $475.92K | -79.89% |
| 2021-01-31 | $2.37 Million | -- |